Important Update: 

The U.S. Food and Drug Administration (FDA) has classified Biocon Biologics’ insulin facilities in Johor Bahru, Malaysia as Voluntary Action Indicated (VAI).
This relates to the cGMP inspection conducted by the agency between September 15 – 27, 2024. The inspection scope included several biologics manufacturing units comprising one (1) Drug Substance and one (1) Drug Product manufacturing units, one (1) Medical Device Assembly unit, one (1) Analytical Quality Control Laboratory, two (2) Microbiological Control Laboratories and two (2) Warehouses.

“Biocon Biologics remains committed to global standards of Quality and Compliance.”– Company Spokesperson

Read More: